Shenouda Maged purchased $844K of RLMD

Shenouda Maged (Chief Financial Officer) purchased 200,000 shares of RELMADA THERAPEUTICS, INC. (RLMD) at an average of $4.22 ($4.20–$4.25, $0.84M total) across 2 trades over 2026-09-09 to 2026-09-10.

Original reporting
SEC EDGAR · Shenouda Maged
Published Sep 11, 2026, 11:30 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 11, 2026, 12:00 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$RLMD
Neutral
medium confidence
Mentioned
$RLMD
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RLMDNeutralLow
01

Why it matters

The CFO's purchase adds to his ownership, indicating personal confidence, but the modest size limits market reaction.

02

Market read

Primary insider purchase filing; modest size suggests limited immediate trading impact.

03

What to watch

Potential upcoming clinical data releases or financing events not disclosed in this filing.

Relevance 6/10Novelty 7/10Timing: filed today

Background

Form 4 disclosures provide transparent reporting of insider transactions required by the SEC.

Company-level read

Ticker impact

$RLMDNeutralMedium confidence
Context

CFO Shenouda Maged purchased 200,000 shares for $844K, increasing his stake to 1,000,000 shares.

Expected impact

Potential slight upside pressure if market perceives confidence, but limited effect.

Evidence & confidence

The purchase is a primary Form 4 filing, providing new information, yet the dollar size is under $1M, reducing material impact.

Market effects

Minimal; biotech sector may note insider confidence but no broader shift.

U.S. market only, no regional ripple.

Low; limited to RLMD investors.

Counterpoint

Insider purchase could be routine portfolio rebalancing rather than a bullish signal.

Key entities

  • Shenouda Maged

    Chief Financial Officer of Relmada Therapeutics

  • Relmada Therapeutics, Inc.

    Biopharmaceutical company developing treatments for neuropsychiatric disorders

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$RLMDMedAI 8/10

Relmada (RLMD) Q3 2026 Earnings Call Transcript

Relmada (RLMD) reported Q3 2026 progress, including IND submissions for NDV-01 and sepranolone by year-end. NDV-01 showed 86% 18-month CR rate in NMIBC, with favorable safety. Phase 3 trials planned. Cash position of $202.1M expected to fund operations through 2029. Net loss was $13.9M, up from $10.1M YoY.

$RLMDHigh

Relmada Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

RELMADA THERAPEUTICS, INC. (RLMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Relmada Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update ● NDV-01 CMC program on track to submit the IND by year-end 2026, with initiation of the registrational Phase 3 SPECTRUM program upon IND clearance ● Long-term extension ND

$RLMDMed

Relmada (RLMD) Q2 2026 Earnings Call Transcript

Relmada Therapeutics (RLMD) reported Q2 2026 results and an execution update. Cash was $217.7M at June 30, 2026, funding operations through 2029. Net loss was $12.9M ($0.11/share). Management expects IND filings for NDV-01 and sepranolone by end-2026 and Phase 3 RESCUE enrollment to start after IND clearance.

$RLMDMed

Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

RELMADA THERAPEUTICS, INC. (RLMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update ● Advancing NDV-01 toward IND filing expected by year-end 2026 with GMP manufacturing of clinical trial material underway. Initiation of the Phase 3 RESCUE registrational